Atika Capital Management LLC Lowers Stock Holdings in Dianthus Therapeutics, Inc. $DNTH

Atika Capital Management LLC trimmed its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 4.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 128,800 shares of the company’s stock after selling 5,728 shares during the period. Dianthus Therapeutics comprises 1.4% of Atika Capital Management LLC’s investment portfolio, making the stock its 17th largest position. Atika Capital Management LLC owned 0.24% of Dianthus Therapeutics worth $10,809,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Sei Investments Co. grew its position in Dianthus Therapeutics by 566.3% during the first quarter. Sei Investments Co. now owns 92,229 shares of the company’s stock valued at $7,741,000 after acquiring an additional 78,388 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Dianthus Therapeutics by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after acquiring an additional 139 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Dianthus Therapeutics by 54.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 325,440 shares of the company’s stock worth $27,296,000 after acquiring an additional 114,767 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Dianthus Therapeutics by 119.7% in the 1st quarter. Swiss National Bank now owns 69,000 shares of the company’s stock worth $5,790,000 after acquiring an additional 37,600 shares during the last quarter. Finally, Jennison Associates LLC bought a new stake in shares of Dianthus Therapeutics in the 1st quarter worth approximately $40,713,000. Institutional investors own 47.53% of the company’s stock.

Insider Buying and Selling at Dianthus Therapeutics

In other news, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the transaction, the executive vice president directly owned 31,249 shares in the company, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Simrat Randhawa sold 26,530 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $362,480. This trade represents a 86.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 87,779 shares of company stock valued at $7,985,235. Corporate insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH opened at $104.79 on Friday. The firm’s 50-day moving average price is $90.36 and its 200-day moving average price is $75.75. The company has a market capitalization of $5.73 billion, a PE ratio of -25.37 and a beta of 1.20. Dianthus Therapeutics, Inc. has a 1-year low of $18.08 and a 1-year high of $107.99.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The company had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.40 million. Equities analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on DNTH. Wedbush raised their price objective on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Raymond James Financial restated a “strong-buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $117.82.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.